secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2024-05-23T23:59:59+00:00
Accession:  0001437749-24-018140
Event type: other
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica shareholders approve 3M share increase to 2019 Omnibus Incentive Plan
-------------------------------------------------------------------------------

- Shareholders approved amendment to increase shares available under 2019 Omnibus Incentive Plan by 3,000,000 shares.
- All seven director nominees elected with >13.5M votes each; broker non-votes of ~11.77M.
- Baker Tilly US, LLP appointed as independent auditor for FY2024 with 24.97M votes for.
- Advisory vote on executive compensation passed (13.18M for); shareholders prefer one-year say-on-pay frequency.
- 67.9% of outstanding shares (25.77M of 37.96M) voted at the annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924018140/0001437749-24-018140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774924018140/dmtp20240523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-018140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer